161 related articles for article (PubMed ID: 11404498)
1. Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer.
Murad AM; Guimarães RC; Aragão BC; Scalabrini-Neto AO; Rodrigues VH; Garcia R
Am J Clin Oncol; 2001 Jun; 24(3):264-8. PubMed ID: 11404498
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
Murad AM
Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):26-32. PubMed ID: 14768402
[TBL] [Abstract][Full Text] [Related]
3. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
Mavroudis D; Malamos N; Alexopoulos A; Kourousis C; Agelaki S; Sarra E; Potamianou A; Kosmas C; Rigatos G; Giannakakis T; Kalbakis K; Apostolaki F; Vlachonicolis J; Kakolyris S; Samonis G; Georgoulias V
Ann Oncol; 1999 Feb; 10(2):211-5. PubMed ID: 10093691
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer.
Murad AM; Guimaraes RC; Amorim WC; Morici AC; Ferreira-Filho AF; Schwartsmann G
Breast Cancer Res Treat; 1997 Aug; 45(1):47-53. PubMed ID: 9285116
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine/paclitaxel as first-line treatment of advanced breast cancer.
Delfino C; Caccia G; Riva Gonzáles L; Mickiewicz E; Rodger J; Balbiani L; Flores Morales D; Zori Comba A; Brosio C
Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):22-5. PubMed ID: 14768401
[TBL] [Abstract][Full Text] [Related]
6. High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients.
Vici P; Capomolla E; Foggi P; Carpano S; Conti F; Paoletti G; Cauchi C; Giacinti L; Leonetti C; Giannarelli D; Lopez M
J Exp Clin Cancer Res; 2006 Mar; 25(1):39-44. PubMed ID: 16761616
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.
Demiray M; Kurt E; Evrensel T; Kanat O; Arslan M; Saraydaroglu O; Ercan I; Gonullu G; Gokgoz S; Topal U; Tolunay S; Tasdelen I; Manavoglu O
Cancer Invest; 2005; 23(5):386-91. PubMed ID: 16193637
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience.
Passardi A; Massa I; Zoli W; Gianni L; Milandri C; Zumaglini F; Nanni O; Maltoni R; Frassineti GL; Amadori D
BMC Cancer; 2006 Mar; 6():76. PubMed ID: 16551351
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Iaffaioli RV; Tortoriello A; Santangelo M; Turitto G; Libutti M; Benassai G; Frattolillo A; Ciccarelli PD; De Rosa P; Crovella F; Carbone I; Barbarisi A
Clin Oncol (R Coll Radiol); 2000; 12(4):251-5. PubMed ID: 11005695
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and paclitaxel as salvage therapy in metastatic breast cancer.
Murad AM; Guimarães RC; Aragão BC; Scalabrini'Neto AO; Rodrigues VH; Garcia R
Oncology (Williston Park); 2001 Feb; 15(2 Suppl 3):25-7. PubMed ID: 11252885
[TBL] [Abstract][Full Text] [Related]
11. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
Liu FS; Ho ES; Hung MJ; Hwang SF; Lu CH; Ke YM
Gynecol Oncol; 2004 Aug; 94(2):393-7. PubMed ID: 15297178
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
[TBL] [Abstract][Full Text] [Related]
13. A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Karachaliou N; Kouroussis Ch; Papakotoulas P; Kalbakis K; Tryfonidis K; Vardakis N; Poppis E; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2012 May; 69(5):1345-52. PubMed ID: 22349809
[TBL] [Abstract][Full Text] [Related]
14. Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens.
Sánchez-Escribano Morcuende R; Alés-Martínez JE; Aramburo González PM
Clin Transl Oncol; 2007 Jul; 9(7):459-64. PubMed ID: 17652060
[TBL] [Abstract][Full Text] [Related]
15. First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study.
Allouache D; Gawande SR; Tubiana-Hulin M; Tubiana-Mathieu N; Piperno-Neumann S; Mefti F; Bozec L; Genot JY
BMC Cancer; 2005 Nov; 5():151. PubMed ID: 16316459
[TBL] [Abstract][Full Text] [Related]
16. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Park YH; Im SA; Kim SB; Sohn JH; Lee KS; Chae YS; Lee KH; Kim JH; Im YH; Kim JY; Kim TY; Lee KH; Ahn JH; Kim GM; Park IH; Lee SJ; Han HS; Kim SH; Jung KH;
Eur J Cancer; 2017 Nov; 86():385-393. PubMed ID: 29100193
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine plus doxorubicin as first-line treatment in advanced or metastatic breast cancer (MBC), a phase II study.
El Serafi MM; El Khodary AI; El Zawahry HR; Mansour OM; Gaballa HE
J Egypt Natl Canc Inst; 2006 Sep; 18(3):209-15. PubMed ID: 17671530
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.
Brufsky A; Hoelzer K; Beck T; Whorf R; Keaton M; Nadella P; Krill-Jackson E; Kroener J; Middleman E; Frontiera M; Paul D; Panella T; Bromund J; Zhao L; Orlando M; Tai F; Marciniak MD; Obasaju C; Hainsworth J
Clin Breast Cancer; 2011 Aug; 11(4):211-20. PubMed ID: 21723792
[TBL] [Abstract][Full Text] [Related]
19. Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial.
Laufman LR; Spiridonidis CH; Pritchard J; Roach R; Zangmeister J; Larrimer N; Moore T; Segal M; Jones J; Patel T; Gutterman L; Carman L; Colborn D; Kuebler JP
Ann Oncol; 2001 Sep; 12(9):1259-64. PubMed ID: 11697837
[TBL] [Abstract][Full Text] [Related]
20. Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
Murialdo R; Bertolotti F; Pastorino G; Mencoboni M; Bergaglio M; Folco U; Cinzia N; Vaira F; Simoni C; Canobbio L; Parodi M; Brema F; Ballestrero A
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1009-16. PubMed ID: 21327683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]